Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma
研究概览
详细说明
OBJECTIVES
Primary To estimate the overall response rate (ORR) (complete response (CR) + very good partial response (VGPR) + partial response (PR)) of patients with multiple myeloma who have relapsed or are refractory after bortezomib treatment and will now receive a combination therapy of simvastatin, zoledronic acid, bortezomib, bendamustine and methylprednisolone.
To evaluate safety and tolerability of studied therapy.
Secondary
- To estimate the progression-free Survival (PFS), time to progression (TTP), overall survival (OS) and duration of response (DOR).
- To describe toxicities (frequency and severity) during the treatment. 3 To estimate clinical benefit response (CBR) (ORR + minor response (MR)) and stable disease (SD).
4 Explore factors associated with ORR, PFS, OS, toxicity.
研究类型
阶段
- 阶段2
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients must have a diagnosis of Multiple Myeloma (using the International Myeloma Working Group Guidelines)
- Patients must have failed at least one prior treatment regimen containing bortezomib.
They may be refractory to primary therapy or relapsed and have measurable or assessable disease. (Refractory disease is defined as anything less than PR or progression within 60 days of completing therapy.)
- Patients with Multiple Myeloma must have measurable active, progressive or symptomatic disease. Measurable disease may be paraprotein or free light chains in serum or urine, or the presence of bone marrow plasma cells.
- Age- must be at least 18 years of age.
- Prior therapies may include bendamustine, bortezomib, methylprednisolone, radiation, and autologous hematopoietic cell transplant.
- Patients who have received therapy must be at least 4 weeks beyond prior chemotherapy (excluding corticosteroids).
- If female patient with reproductive capacity: on effective means of birth control during the entire duration of the treatment.
- Patients must have recovered from acute toxicities resulting from therapy administered prior to entering this study to grade 1 or less. Alopecia may not be resolved.
- Ability to understand and willingness to sign a written informed consent document.
- Life expectancy of greater than 8 weeks.
- ECOG performance status 0, 1, or 2 (Karnofsky > 60%; see Appendix A).
- Patients must have adequate bone marrow function as defined below:
absolute neutrophil count > 500/ul platelets > 30,000/ul
-Patients must have adequate liver function as defined below: total bilirubin < 2 times the upper limit of normal AST(SGOT), ALT(SGPT) < 3 x upper limit of normal
- Patients must have adequate renal function as defined by a creatinine clearance > 40 mL/min (measured or estimated by the Cockcroft-Gault formula).
- Patients must have no signs of significant rhabdomyolysis determined by CPK levels with a CK < 5 times the upper limit of normal.
Exclusion Criteria:
- Patients who have not received any chemotherapy treatment for multiple myeloma prior to being enrolled in the study.
- Patients who were receiving simvastatin (dose > 40 mg/day), or the equivalent dose of another statin) during last prior chemotherapy for multiple myeloma.
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Patients receiving any other investigational agent(s).
- Active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ.
- History of hypersensitivity reactions attributed to simvastatin, bortezomib, bendamustine or zoledronic acid.
- Pregnant women are ineligible, as treatment involves unforeseeable risks to the embryo or fetus.
- Patients receiving medications that may increase risk of rhabdomyolysis such as itraconazole, ketoconazole, erythromycin, cyclosporine, amiodarone, verapamil, niacin, HIV protease inhibitors.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myopathy, untreated hypothyroidism, hereditary myopathy in the family history, unstable angina pectoris, liver disease not due to multiple myeloma, cardiac arrhythmia that is symptomatic or not rate controlled, active connective tissue disease, active autoimmune disease, or psychiatric illness/social situations that would limit compliance with study requirements.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment with combination therapy
Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
|
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Response to treatment as defined by The International Myeloma Working Group response criteria for multiple myeloma.
大体时间:4 weeks after first dose of simvastatin
|
Response catergories (IMWG): Complete Remission(CR), Very Good Partial Remission(VGPR), Partial Remission (PR), Minor Response (MR), Progressive Disease (PD), Stable Disease, Relapse,Refractory Disease, Overall Response. |
4 weeks after first dose of simvastatin
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression Free Survival (PFS)
大体时间:After 1 year of follow-up.
|
PFS is measured from date of study enrollment until the date of progressive disease is documented.
|
After 1 year of follow-up.
|
|
Incidence Rate of Toxicity
大体时间:End of study; monitoring during study.
|
Decriptive statistics will be provided regarding incidence rates of toxcity.
Patients will be monitored for safety throughout the study.
|
End of study; monitoring during study.
|
|
Overall Survival (OS)
大体时间:After 1 year of follow-up
|
OS is measured from date of study enrollment until death.
|
After 1 year of follow-up
|
合作者和调查者
调查人员
- 首席研究员:Geoffrey Herzig, MD、James Graham Brown Cancer Center- University of Louisville
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 心血管疾病
- 血管疾病
- 免疫系统疾病
- 组织学类型的肿瘤
- 肿瘤
- 淋巴增生性疾病
- 免疫增生性疾病
- 血液病
- 出血性疾病
- 止血障碍
- 副蛋白血症
- 血液蛋白失调
- 多发性骨髓瘤
- 肿瘤,浆细胞
- 药物的生理作用
- 药理作用的分子机制
- 自主代理
- 周围神经系统药物
- 酶抑制剂
- 止痛药
- 感觉系统代理
- 抗炎药,非甾体
- 镇痛药,非麻醉药
- 抗炎药
- 抗风湿药
- 环氧合酶抑制剂
- 抗代谢物
- 抗肿瘤药
- 止吐药
- 胃肠道药物
- 糖皮质激素
- 荷尔蒙
- 激素、激素替代品和激素拮抗剂
- 抗肿瘤药,激素
- 神经保护剂
- 保护剂
- 抗肿瘤药,烷基化
- 烷化剂
- 抗胆固醇药物
- 降血脂药
- 脂质调节剂
- 羟甲基戊二酰辅酶 A 还原酶抑制剂
- 骨密度保护剂
- 泼尼松龙
- 醋酸甲泼尼龙
- 甲泼尼龙
- 琥珀酸甲泼尼龙
- 醋酸泼尼松龙
- 泼尼松龙半琥珀酸盐
- 磷酸泼尼松龙
- 盐酸苯达莫司汀
- 硼替佐米
- 双氯芬酸
- 唑来膦酸
- 辛伐他汀
其他研究编号
- BCC-HEM-10-001
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.